Public offering nets $43.3mm for Regulus

19:41 EDT 24 Jul 2017 | Elsevier Business Intelligence

Regulus Therapeutics Inc. (microRNA-based treatments for liver and kidney conditions and cancer) netted $43.3mm though a publ...

Original Article: Public offering nets $43.3mm for Regulus


More From BioPortfolio on "Public offering nets $43.3mm for Regulus"

Quick Search

Relevant Topics

MicroRNAs (miRNAs)
A microRNA (abbreviated miRNA) is a small non-coding RNA molecule (containing about 22 nucleotides) found in plants, animals, and some viruses.  Key findings: miRNA is involved in the normal functioning of eukaryotic cells, so has dysregulation...

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...